Dr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder Cancer

John Wagstaff, MD
Published: Friday, Oct 06, 2017



John Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer.

Most of the trials have been conducted with single-agent checkpoint inhibitors, explains Wagstaff. These trials showed response rates in the second-line setting of 15% to 25%.

Patients with melanoma who respond to immunotherapy see years of survival benefit; however, longer follow-up is needed to determine if this is the case in bladder cancer, states Wagstaff.
 


John Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer.

Most of the trials have been conducted with single-agent checkpoint inhibitors, explains Wagstaff. These trials showed response rates in the second-line setting of 15% to 25%.

Patients with melanoma who respond to immunotherapy see years of survival benefit; however, longer follow-up is needed to determine if this is the case in bladder cancer, states Wagstaff.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x